Emergent BioSolutions (NYSE:EBS) Sets New 52-Week High at $13.23

Emergent BioSolutions Inc. (NYSE:EBS)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $13.23 and last traded at $13.14, with a volume of 1045719 shares changing hands. The stock had previously closed at $12.49.

Analyst Upgrades and Downgrades

Separately, Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, July 2nd.

Emergent BioSolutions Stock Up 10.5 %

The stock’s fifty day moving average is $7.22 and its 200 day moving average is $4.10. The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $723.12 million, a P/E ratio of -1.23 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. The company had revenue of $300.40 million during the quarter. During the same quarter in the prior year, the company earned ($3.17) earnings per share. Research analysts predict that Emergent BioSolutions Inc. will post -1.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the completion of the transaction, the director now directly owns 54,482 shares in the company, valued at approximately $332,885.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 12,919 shares of company stock worth $75,831. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. SeaCrest Wealth Management LLC raised its holdings in Emergent BioSolutions by 19.8% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 114,995 shares of the biopharmaceutical company’s stock worth $784,000 after purchasing an additional 18,995 shares in the last quarter. Baader Bank Aktiengesellschaft bought a new position in shares of Emergent BioSolutions in the 2nd quarter worth about $235,000. CWM LLC increased its stake in shares of Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 4,906 shares in the last quarter. Cetera Advisors LLC bought a new position in shares of Emergent BioSolutions in the 1st quarter worth about $428,000. Finally, Tidal Investments LLC bought a new position in shares of Emergent BioSolutions in the 1st quarter worth about $34,000. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.